Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05506215 · ClinicalTrials.gov registry record · NA
Randomized Clinical Study Comparing SynPath to Standard of Care in Treatment of Chronic Diabetic Foot Ulcers
A NA study, sponsored by PolyNovo Biomaterials Pty.
- Terminated
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT05506215 is a NA study that was terminated before completion, run by PolyNovo Biomaterials Pty. The registered enrollment target is 25 participants.
The verdict
NCT05506215, a NA study, was terminated before completion, sponsored by PolyNovo Biomaterials Pty.
- TERMINATED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy of SynPath™, a synthetic dermal matrix, in the treatment of diabetic foot ulcers in subjects with diabetes mellitus versus Standard of Care treatment. Half the subjects with be treated using SynPath™ while the other half will receive Standard of Care treatment
Interventions
- DEVICE SynPath Acellular Dermal Matrix plus Off-loading Device
- DEVICE Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-07-10 |
| Est. Completion | 2024-02-26 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05506215
The ClinicalTrials.gov registry entry for NCT05506215 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PolyNovo Biomaterials Pty, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SynPath Acellular Dermal Matrix plus Off-loading Device is the first listed.
NCT05506215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05506215 about?
NCT05506215 is a clinical study titled "Randomized Clinical Study Comparing SynPath to Standard of Care in Treatment of Chronic Diabetic Foot Ulcers". The study will evaluate the efficacy of SynPath™, a synthetic dermal matrix, in the treatment of diabetic foot ulcers in subjects with diabetes mellitus versus Standard of Care treatment. Half the subjects with be treated using SynPath™ while the other half will receive Standard of Care treatment
What is the current status of trial NCT05506215?
This trial is currently terminated. It is a NA study. The enrollment target is 25 participants. The study started on 2022-07-10. Estimated completion is 2024-02-26.
What interventions are being tested in trial NCT05506215?
The interventions under investigation include: SynPath Acellular Dermal Matrix plus Off-loading Device (DEVICE), Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device (DEVICE).
Who is sponsoring clinical trial NCT05506215?
This trial is sponsored by PolyNovo Biomaterials Pty, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.